Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
BOSTON, Oct. 9, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Trevena, Inc. ("Trevena" or the "Company") (NASDAQ: TRVN) and certain of its officers and directors violated federal securities laws.
On May 2, 2016, the Company announced that it had "reached general agreement" with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was "very pleased" with the outcome of its discussions with the FDA.
In fact, FDA minutes from its April 28, 2016 meeting with the Company—revealed today—show that the FDA:
- "did not agree with the proposed dosing in the Phase 3 studies";
- "did not agree with the proposed primary endpoint"; and
- "did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine"
The Company's stock price has plunged more than 60%.
If you have purchased or otherwise acquired Trevena securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorneys John DeFelice or Jake Walker at (888) 868-2385, by email at [email protected] or [email protected], or by visiting http://shareholder.law/trevena.
Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110
[email protected]
SOURCE Block & Leviton LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article